CompletedPhase 2

Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation

Austria20 participantsStarted 2013-06

Plain-language summary

The purpose of this study is to investigate the effect of orally inhaled AP-301 on primary graft dysfunction after lung transplantation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Being a male or female recipient on the AKH's waiting list for primary single or double LuTX * PGD score ≥ 1 within 72 hours after LuTX * Informed consent is available Exclusion Criteria: * History of clinically relevant allergies or idiosyncrasies to AP301 or any other inactive ingredient(s) of the investigational product * Postoperative ECMO support * Paediatric /adolescent recipients (\< 18 years) * Lobar transplantation * Retransplantation * Combined solid organ transplants * Participation in other drug trials

What they're measuring

P/F ratio

Timeframe: 7 days

Trial details

NCT IDNCT02095626

SponsorApeptico Forschung und Entwicklung GmbH

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-03

View on ClinicalTrials.gov More PGD Primary Graft Dysfunction trials